Pioneering Transplant Science and Technology
HLA Institute leads in leveraging new technologies for immunogenetics, clinical xenotransplantation, and post-transplant surveillance to improve patient outcomes.
HLA Institute — Institutional Profile
HLA Institute was established in 2019 by Rose Genomics Corp. Ltd., dedicated to the research and development of Human Leukocyte Antigen (HLA) typing technologies, histocompatibility testing for solid organ and hematopoietic stem cell transplantation, HLA antibody screening, xenotransplantation tissue matching (pig-to-human), hyperacute rejection monitoring, safe transfusion diagnostics, and transplant immunogenomics bioinformatics.
Core R&D Focus:
Bioinformatics Platform: HLA/SLA allele database curation, annotation pipelines, and automated compatibility reporting tools
Safe Transfusion Diagnostics: HLA / HPA / RBC genotyping for platelet and red blood cell alloantibody risk reduction
Xenotransplantation Compatibility: Porcine Leukocyte Antigen (SLA) NGS sequencing & pig–human HLA/SLA cross-matching, with pre- and post-transplant rejection surveillance (including dd-cfDNA monitoring)
Antibody Detection: Panel Reactive Antibody (PRA) and Donor-Specific Antibody (DSA) screening to assess recipient sensitization status
HLA Tissue Typing: High-resolution HLA genotyping (NGS / SBT-based) for pre-transplant donor-recipient matching—kidney, liver, heart, and HSCT
Academic & Commercial Activities:
The Institute organizes technical seminars and professional training programs, promotes domestic and international academic exchange, and offers technology licensing / transfer and collaborative R&D services to hospitals, laboratories, and biotech partners.
Research Excellence in Transplant & Immunogenetics
Our institute harnesses the latest advances in HLA typing, histogenetics, and bioinformatics to deliver precise tissue compatibility testing and rejection monitoring critical for xenotransplantation success.
Why Our Research Advances Transplant Medicine
Cutting-edge technology, expert team, and focused clinical applications.
High-Resolution
NGS-Based HLA Typing
Next-generation sequencing delivers unambiguous, phase-resolved HLA genotyping across 11 loci (HLA-A, -B, -C, -DRB1/3/4/5, -DQA1, -DQB1, -DPA1, -DPB1), providing gold-standard pre-transplant matching for solid organ and HSCT
xenotransplantation Tissue Compatibility (SLA ↔ HLA)
Pioneering porcine leukocyte antigen (SLA) NGS sequencing and pig-to-human cross-matching to predict hyperacute rejection pre-transplant and guide genetically edited donor-pig selection.
Non-Invasive Rejection Surveillance via dd-cfDNA
IProprietary donor-derived cell-free DNA (dd-cfDNA) assay enables sensitive, real-time post-transplant monitoring—detecting graft injury earlier than conventional biomarkers and reducing reliance on protocol biopsies.
In-House Bioinformatics & Curated Databases
Independently developed HLA/SLA allele databases and annotation pipelines aligned with the latest IPD-IMGT/HLA release, powering automated compatibility reporting.
Technology Transfer & Training
We offer professional training programs, academic exchange platforms, and customized technology licensing/collaborative R&D for transplant centers and diagnostic labs worldwide.
Stem Cell Research Project
Robust post-transplant monitoring ensuring early detection of organ rejection for timely intervention.
15+
Years of Research Excellence
120+
Published Scientific Papers
30+
Successful Clinical Collaborations